Cyclenium, Fundación MEDINA Drug Discovery Agreement
News Feb 24, 2015
Cyclenium Pharma Inc. and Fundación MEDINA (Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía) have announced the signing of a drug discovery and collaboration agreement.
The collaboration will utilize Cyclenium’s proprietary QUEST Library™ of next generation macrocyclic molecules and associated hit-to-clinical candidate optimization capabilities in concert with the extensive expertise and experience of Fundación MEDINA in infective disease research.
The objective of the collaboration is to discover new anti-infective drug candidates effective against a number of clinically important bacterial and fungal pathogens. For Cyclenium, this is the fourth discovery collaboration established over the past year.
“We are extremely excited about entering into this unique drug discovery collaboration with the Fundación MEDINA in one of our therapeutic focus areas,” stated Helmut Thomas, Ph.D., President & Chief Executive Officer of Cyclenium.
Thomas continued, “The combination of their superb team and world class expertise in anti-infective research with our CMRT™ Technology and proven development success in the macrocycle arena offers an excellent opportunity for discovering desperately needed novel pharmaceutical agents against high priority, treatment resistant, bacterial and fungal organisms.”
“This relationship represents a strategic collaboration to identify novel drugs in the area of infectious diseases from the exploitation of Cyclenium’s unique library complementing the chemical diversity of our natural product libraries,” said Olga Genilloud, Ph.D., Scientific Director, Fundación MEDINA. “MEDINA provides the expertise and tools to maximize the probability of success in the collaboration with Cyclenium and the discovery of promising compounds for the treatment of serious multidrug resistant infections.”
Researchers Uncover Muscle Growth Inhibitor Activation Mechanism Aiding ALS Treatment EffortsNews
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for limiting muscle, is activated.READ MORE
New Research Could Significantly Accelerate Drug DiscoveryNews
Scientists have developed a suite of computer programs that cull through data on structure and genomic sequencing to identify the features that distinguish one enzyme from similar enzymes. This research has the potential to significantly accelerate drug discovery, allowing scientists to develop more effective drugs, more quickly.READ MORE
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.